BTG plc (BTG) Given Buy Rating at Jefferies Group
BTG has been the topic of a number of other reports. Numis Securities Ltd upgraded BTG plc to a buy rating and set a GBX 900 ($11.24) price objective on the stock in a research report on Monday, October 17th. Deutsche Bank AG restated a buy rating on shares of BTG plc in a research report on Friday, October 7th. JPMorgan Chase & Co. boosted their price objective on BTG plc from GBX 790 ($9.87) to GBX 830 ($10.37) and gave the company a neutral rating in a research report on Friday, October 7th. Royal Bank Of Canada cut BTG plc to a sector performer rating and lowered their price objective for the company from GBX 910 ($11.37) to GBX 790 ($9.87) in a research report on Tuesday, November 1st. Finally, Stifel Nicolaus restated a hold rating and set a GBX 640 ($8.00) price objective on shares of BTG plc in a research report on Thursday, October 6th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. BTG plc presently has an average rating of Buy and an average price target of GBX 820 ($10.24).
BTG plc (LON:BTG) traded up 0.49% during trading on Wednesday, reaching GBX 619.00. 962,885 shares of the company’s stock were exchanged. The company’s market capitalization is GBX 2383.64 billion. The stock’s 50-day moving average price is GBX 661.45 and its 200-day moving average price is GBX 649.86. BTG plc has a 52-week low of GBX 554.97 and a 52-week high of GBX 739.50.
BTG plc Company Profile
BTG plc is engaged in the business of healthcare, focusing on Interventional Medicine therapies for liver cancer, emphysema and vascular disorders, specialty pharmaceuticals for acute care uses, and a licensing business. The Company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals and Licensing.
Receive News & Stock Ratings for BTG plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BTG plc and related stocks with our FREE daily email newsletter.